Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …

Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in
modern drug development. By harnessing the powers of both cytotoxic chemotherapy and …

MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs).
These alterations are associated with increased MET activity and preclinical sensitivity to …

Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer
care, an urgent need exists for a clinical support tool that distills the clinical implications …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

Purpose Non–small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and
its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical …

The MET oncogene encodes an unconventional receptor tyrosine kinase with pleiotropic
functions: it initiates and sustains neoplastic transformation when genetically altered …